During the last session, Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL)’s traded shares were 1.08 million, with the beta value of the company hitting 1.80. At the end of the trading day, the stock’s price was $10.98, reflecting an intraday loss of -6.67% or -$0.79. The 52-week high for the ZNTL share is $31.46, that puts it down -186.52 from that peak though still a striking 12.93% gain since the share price plummeted to a 52-week low of $9.56. The company’s market capitalization is $779.50M, and the average trade volume was 824.90K shares over the past three months.
Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) trade information
Zentalis Pharmaceuticals Inc (ZNTL) registered a -6.67% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -6.67% in intraday trading to $10.98, hitting a weekly high. The stock’s 5-day price performance is -12.40%, and it has moved by -22.04% in 30 days. Based on these gigs, the overall price performance for the year is -49.59%.
Zentalis Pharmaceuticals Inc (ZNTL) estimates and forecasts
Statistics show that Zentalis Pharmaceuticals Inc has outperformed its competitors in share price, compared to the industry in which it operates. Zentalis Pharmaceuticals Inc (ZNTL) shares have gone down -34.10% during the last six months, with a year-to-date growth rate more than the industry average at 16.78% against 12.90.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 13.12M as predicted by 8 analyst(s).
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -50.05%. While earnings are projected to return 18.03% in 2024.
ZNTL Dividends
Zentalis Pharmaceuticals Inc is due to release its next quarterly earnings in May. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
